GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Solid Biosciences Inc.
Solid Biosciences is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy. Its stock price is highly volatile, reflecting the hopes and setbacks of its multi-year clinical trials.
Share prices of companies in the market segment - Dna
Solid Biosciences is a biotechnology company focused on developing gene therapies for Duchenne muscular dystrophy and other neuromuscular diseases. We classify it in the DNA Technologies sector. The chart below illustrates the overall dynamics of this cutting-edge field of medicine.
Broad Market Index - GURU.Markets
Solid Biosciences is a biotech company specializing in developing gene therapy for Duchenne muscular dystrophy. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Solid shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SLDB - Daily change in the company's share price Solid Biosciences Inc.
Daily fluctuations in Solid Biosciences, which works on gene therapy for muscular dystrophy, reflect the high risks of the biotech sector. Change_co is an immediate reaction to news about clinical trials. This indicator forms the basis for analysis of the advanced biotech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Solid Biosciences Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with the performance of SLDB, which focuses on treating muscular dystrophy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Solid Biosciences is a biopharmaceutical company specializing in gene therapy for Duchenne muscular dystrophy. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Solid's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Solid Biosciences Inc.
Solid Biosciences' year-to-date performance reflects its long-standing struggle to develop gene therapy for Duchenne muscular dystrophy. Its market capitalization over the past 12 months is fundamentally dependent on news from clinical trials. Any data on the safety and efficacy of its drug could either restore hope or cast doubt on the company's future.
Annual dynamics of market capitalization of the market segment - Dna
Solid Biosciences Inc. is a biotech company developing gene therapy for Duchenne muscular dystrophy. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Solid Biosciences is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Solid Biosciences Inc.
The valuation of Solid, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its gene therapy for Duchenne muscular dystrophy, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Dna
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy, a rare and fatal genetic disease. The graph below illustrates the dynamics of the biotech sector, where advances in gene therapy could dramatically change patients' lives.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Solid Biosciences is a biotech company focused on gene therapy for Duchenne muscular dystrophy. It's a classic example of a company whose fate hinges on one or two drugs in development. Its stock moves solely on news of clinical trials, not the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Solid Biosciences Inc.
Solid Biosciences is a biotech company developing gene therapy for Duchenne muscular dystrophy. Its weekly stock price is extremely volatile, depending on news about the safety and efficacy of its clinical trials.
Weekly dynamics of market capitalization of the market segment - Dna
Solid Biosciences, like the entire gene therapy sector, is extremely volatile. Weekly stock price fluctuations in this segment often reflect broader scientific breakthroughs or setbacks, which impact investor interest in the entire sector. The chart shows how the company is tracking this overall biotech trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Solid Biosciences is a biotech company working in gene therapy. Its shares follow the rhythm of clinical trial news. This chart is a great way to see how its weekly fluctuations are detached from overall market trends, following their own unique trajectory.
Market capitalization of the company, segment and market as a whole
SLDB - Market capitalization of the company Solid Biosciences Inc.
The chart of Solid Biosciences tells the dramatic story of the search for a cure for Duchenne muscular dystrophy. Its volatile market cap reflects all the ups and downs of the biotech world: from hopes for gene therapy to disappointments from clinical trial results and regulatory decisions.
SLDB - Share of the company's market capitalization Solid Biosciences Inc. within the market segment - Dna
Solid Biosciences Inc. is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy. Its market share and market capitalization reflect the promise and risks associated with developing a cure for this devastating disease.
Market capitalization of the market segment - Dna
Solid Biosciences is developing gene therapy for muscular dystrophy. How big is this arena of hope? The chart below shows the pulse of the DNA technology sector. Its extreme volatility reflects both the enormous potential for treating rare diseases and the high risk of clinical failure.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Solid Biosciences chart shows the dramatic story of developing a gene therapy for Duchenne muscular dystrophy. Its market capitalization reflects all the ups and downs associated with clinical trials, including pauses and restarts. It's a chart full of the hopes and disappointments typical of breakthrough biotech.
Book value capitalization of the company, segment and market as a whole
SLDB - Book value capitalization of the company Solid Biosciences Inc.
For Solid Biosciences, a company developing a gene therapy for Duchenne muscular dystrophy, book value is its tangible foundation: laboratories, manufacturing contracts, and financial reserves for clinical trials. The chart below shows how the company built this foundation for its research.
SLDB - Share of the company's book capitalization Solid Biosciences Inc. within the market segment - Dna
Solid Biosciences is a gene therapy company whose tangible assets include cutting-edge laboratories and, crucially, its own AAV vector production facility. This facility is the physical foundation of its ability to create drugs. The chart shows the share of this unique biotech infrastructure the company controls.
Market segment balance sheet capitalization - Dna
Solid Biosciences is a gene therapy company. Pharmaceuticals, as the chart shows, are capital-intensive. Solid is a prime example. Its business requires not only R&D but also investment in complex manufacturing processes to create its drugs.
Book value of all companies included in the broad market index - GURU.Markets
Solid Biosciences' resources include laboratories and investments in manufacturing facilities for developing gene therapy for Duchenne muscular dystrophy. The chart below shows how the company built its scientific and physical capital to address this complex challenge.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Solid Biosciences Inc.
Solid Biosciences is a biotech company. Its market valuation is a pure bet on the success of its gene therapy. The chart is a roller coaster of hopes and disappointments related to clinical trial results.
Market to book capitalization ratio in a market segment - Dna
Solid Biosciences is a biotech company developing gene therapy for Duchenne muscular dystrophy. Its valuation is entirely dependent on the success of its clinical programs. The chart shows a high premium to its stock, reflecting investor expectations.
Market to book capitalization ratio for the market as a whole
Solid Biosciences is a biotech company focused on gene therapy for Duchenne muscular dystrophy. Its current valuation, compared to the average on this chart, is a pure bet on the success of its clinical trials. Investors are evaluating the potential of its drug, not its tangible assets, which is typical for early-stage biotech.
Debts of the company, segment and market as a whole
SLDB - Company debts Solid Biosciences Inc.
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. This chart reflects its financial history, which is full of ups and downs. The company funds its expensive and risky research exclusively with equity capital, depending on the results of clinical trials.
Market segment debts - Dna
Solid Biosciences is a biotech company developing gene therapy for Duchenne muscular dystrophy. This is an extremely complex and risky field. This chart shows how the company's debt policy reflects its need for significant capital to fund multi-year clinical trials and overcome scientific and regulatory hurdles.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Solid Biosciences Inc.
Solid Biosciences is a biotech company focused on gene therapy for Duchenne muscular dystrophy. Developing such complex treatments requires significant investment and time. This chart shows the extent to which the company relies on debt to fund its research, which directly reflects its financial risk in achieving its goal.
Market segment debt to market segment book capitalization - Dna
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its complex and expensive clinical research in this challenging field.
Debt to book value of all companies in the market
Solid Biosciences is a biotech company focused on gene therapy for Duchenne muscular dystrophy. This is a long and expensive research journey. This chart of total market debt serves as an indicator of the investment climate. It shows how willing lenders and investors are to finance high-risk but potentially breakthrough projects.
P/E of the company, segment and market as a whole
P/E - Solid Biosciences Inc.
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy (DMD). This chart reflects the hopes and setbacks in this complex field. Its volatile dynamics are directly related to news about clinical trials, side effects, and the effectiveness of their experimental drugs.
P/E of the market segment - Dna
Solid Biosciences is a biotechnology company focused entirely on developing gene therapy for Duchenne muscular dystrophy, a rare and fatal genetic disorder affecting boys. This chart shows the overall valuation of the DNA technology sector, reflecting investor hopes for a breakthrough in treating this devastating disease.
P/E of the market as a whole
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. Its valuation is a pure bet on the success of its research after a series of previous failures. It is unrelated to the general economic cycles reflected in this chart. Its fate is decided in clinics and by regulators.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Solid Biosciences Inc.
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. This chart reflects the risky expectations of its clinical programs. The company's valuation depends almost entirely on trial results and investor confidence that its approach will be safe and effective.
%20P%2FE%20Solid%20Biosciences%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Solid-Biosciences-Inc.&v=1772588557695 "Chart of the company's future (projected) P/E Solid Biosciences Inc.")
Future (projected) P/E of the market segment - Dna
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. This chart reflects the speculative and risky expectations of investors. Comparing its future revenue forecasts with the sector reveals the market's confidence in the success of its clinical trials and a breakthrough in treating this disease.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772588557703 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Solid Biosciences is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy. This is a highly risky area with enormous potential. This overall risk appetite chart determines the company's ability to attract funding for its expensive and long-term clinical programs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772588557762 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Solid Biosciences Inc.
Solid Biosciences Inc. is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy. The company is in clinical trials. This schedule reflects significant R&D expenditures, and any future profits are contingent on the success of its lead drug candidate.
Profit of companies in the market segment - Dna
Solid Biosciences is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy, a rare and debilitating genetic disorder. The company is at the forefront of scientific advances. Its profitability chart reflects the hopes and disappointments associated with clinical trials and the willingness of investors to finance long-term, risky projects.
Overall market profit
Solid Biosciences is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy, a rare and devastating genetic disorder. The company is at the forefront of science, and its potential success could bring hope to thousands of patients and demonstrate the power of modern biotechnology in the fight against inherited diseases.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Solid Biosciences Inc.
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. This chart shows the highly speculative expectations for its clinical programs. The success or failure of a single key trial could dramatically alter the company's future.
%20profit%20of%20the%20company%20Solid%20Biosciences%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Solid-Biosciences-Inc.&v=1772588558015 "Graph of future (projected) profit of the company Solid Biosciences Inc.")
Future (predicted) profit of companies in the market segment - Dna
Solid Biosciences Inc. is a biotechnology company developing gene therapy for Duchenne muscular dystrophy. This chart shows the expected revenue trend for the biotechnology sector. It helps assess the potential and risks of a company focused on treating a single rare and severe disease.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772588558096 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
The trend in this chart reflects expectations for a biotech company developing gene therapy for Duchenne muscular dystrophy. Solid Biosciences' profit forecast is entirely dependent on clinical trial results. The trajectory reflects investors' faith in the company's science and its potential to solve a complex medical problem.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772588558205 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Solid Biosciences Inc.
Solid Biosciences is a biotech company developing gene therapy for Duchenne muscular dystrophy. It has no commercial revenue. This chart shows a valuation based solely on its belief in its scientific approach and the potential for treating one of the most challenging diseases to treat. It's a pure venture bet.
P/S market segment - Dna
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. The company's valuation is based on the potential of its lead candidate. This chart shows the average valuation in the biotech industry, reflecting investor expectations for Solid Biosciences' future revenue if its clinical programs are successful.
P/S of the market as a whole
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. Its valuation is almost entirely dependent on clinical trial results. This chart, which displays the average revenue estimate for Solid Biosciences, highlights that for companies like this, it's not sales that matter, but rather investors' faith in their scientific potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Solid Biosciences Inc.
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. The company does not yet have any commercial products. This chart reflects investor expectations for a scientific breakthrough. It shows the market's assessment of the likelihood of success in its clinical trials and eventual drug approval.
%20P%2FS%20Solid%20Biosciences%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Solid-Biosciences-Inc.&v=1772588558382 "The graph of the company's future (projected) P/S Solid Biosciences Inc.")
Future (projected) P/S of the market segment - Dna
Solid Biosciences is a biotechnology company developing gene therapy for Duchenne muscular dystrophy. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. The valuation reflects investor expectations for the success of its clinical programs in this complex field.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772588558395 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Solid Biosciences is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy. Its future depends entirely on the success of clinical trials. A potential breakthrough in the treatment of this rare disease is part of the overall optimism surrounding medical innovation, as reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772588558415 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Solid Biosciences Inc.
Solid Biosciences is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy. While in clinical trials, it may not have stable revenues. This graph shows revenues based on commercialization or receipt of royalties from pharmaceutical partners.
Sales of companies in the market segment - Dna
Solid Biosciences Inc. is a biotechnology company focused on developing gene therapies for the treatment of Duchenne muscular dystrophy, a rare and fatal genetic disease. This chart shows overall pharmaceutical sales, illustrating the enormous potential but also the high risks associated with developing breakthrough treatments for orphan diseases.
Overall market sales
Solid Biosciences is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy. This overall economic activity chart for Solid Biosciences is important due to its investment climate. Funding for breakthrough but risky medical research is highly dependent on overall market confidence and capital availability.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Solid Biosciences Inc.
Solid Biosciences is a biotechnology company focused on developing gene therapies for the treatment of Duchenne muscular dystrophy. Currently in the clinical stage, its future revenue is entirely dependent on the success of trials and the approval of its drugs. This chart reflects analysts' speculative expectations regarding the scientific and commercial potential of its developments.
%20sales%20of%20the%20company%20Solid%20Biosciences%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Solid-Biosciences-Inc.&v=1772588558615 "Schedule of future (projected) sales of the company Solid Biosciences Inc.")
Future (projected) sales of companies in the market segment - Dna
Solid Biosciences Inc. is a biotechnology company developing gene therapy for Duchenne muscular dystrophy. This chart shows projected revenue for the entire biotech sector. While it provides a general overview, for Solid Biosciences, the success of clinical trials for its lead drug candidate is crucial.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772588558625 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Solid Biosciences is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy. Its valuation depends solely on progress in clinical trials. This schedule, reflecting overall economic sentiment, impacts the company's ability to attract funding for its expensive and long-term research, which is critical to its survival.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772588558657 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Solid Biosciences Inc.
Solid Biosciences is a biotechnology company focused on gene therapy for Duchenne muscular dystrophy. This chart illustrates the company's financial journey at the forefront of science. This metric reflects its significant investment in clinical trials and research in the hopes of creating a breakthrough drug that will transform patients' lives and generate revenue.
Market segment marginality - Dna
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. This is an extremely complex undertaking. This timeline reflects its operational structure, typical for a clinical-stage biotech, with high R&D costs and no commercial revenue at this stage.
Market marginality as a whole
Solid Biosciences is a biotechnology company specializing in the development of gene therapy for the treatment of Duchenne muscular dystrophy. Its future profitability is entirely dependent on the success of its clinical programs. This total market return chart serves as a contrast to the world of biotechnology, where scientific breakthroughs in treating devastating diseases can create enormous value for society and investors.
Employees in the company, segment and market as a whole
Number of employees in the company Solid Biosciences Inc.
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. This graph shows the team's successes and failures. The team's dynamics reflect the complex and risky stages of clinical trials, including trial pauses and restarts.
Share of the company's employees Solid Biosciences Inc. within the market segment - Dna
This chart illustrates Solid Biosciences' tenacity in the fight against Duchenne muscular dystrophy. A significant portion of the company's employees in this niche biotech sector are focused on developing gene therapy for this rare and fatal disease. This team of scientists, despite past setbacks, continues to work toward developing a potential cure.
Number of employees in the market segment - Dna
Solid Biosciences is a biotechnology company focused on developing gene therapy for Duchenne muscular dystrophy, a rare and debilitating genetic disorder. The company's work brings hope to thousands of patients. This graph illustrates how biotechnology is penetrating the field of orphan diseases, requiring unique scientific expertise.
Number of employees in the market as a whole
Solid Biosciences Inc. is a biotechnology company developing gene therapy for Duchenne muscular dystrophy. Its success depends solely on the results of clinical trials. This general work schedule has nothing to do with its activities, which are focused on solving one of the most complex genetic diseases.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Solid Biosciences Inc. (SLDB)
Solid Biosciences is a biotech company focused on gene therapy for Duchenne muscular dystrophy. This chart demonstrates investors' faith in the science. The company's very high market capitalization per scientist reflects their enormous hopes that their single, yet potentially breakthrough, drug will transform patients' lives and generate billions in revenue.
%20of%20the%20company%20Solid%20Biosciences%20Inc.%20(SLDB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Solid-Biosciences-Inc.-SLDB&v=1772588559013 "Chart of market capitalization per employee (in thousands of dollars) of the company Solid Biosciences Inc. (SLDB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Solid Biosciences is developing a gene therapy for Duchenne muscular dystrophy. Like many biotech companies, its value stems from the hope of a future breakthrough. This chart illustrates the enormous potential value the market sees in research conducted by a small but highly skilled team of scientists.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772588559063 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Solid Biosciences Inc. is a biotech company focused on gene therapy for Duchenne muscular dystrophy. This chart shows an extremely high valuation per employee, reflecting investor hopes for a breakthrough in the treatment of this devastating disease. The company's value is based on its science, not its current revenue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772588559122 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Solid Biosciences Inc. (SLDB)
Solid Biosciences is a biotech company focused on gene therapy for Duchenne muscular dystrophy (DMD). It is a clinical-stage company with no profit. This chart shows the net loss (R&D costs) per scientist. The entire staff is working on developing one of the most complex drugs in the world.
%20Chart%20Solid%20Biosciences%20Inc.%20(SLDB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Solid-Biosciences-Inc.-SLDB&v=1772588559151 "Company Profit Per Employee (in thousands of dollars) Chart Solid Biosciences Inc. (SLDB)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Solid Biosciences is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy. This is an extremely complex and risky field. This graph shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively the company invests in its scientists to achieve scientific breakthroughs, compared to other biotech companies in the same field.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772588559202 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Solid Biosciences (SLDB) is a clinical-stage biotech focused on gene therapy for Duchenne muscular dystrophy. This chart shows a significant loss per employee. It reflects how much the company spends on each scientist and researcher trying to bring its treatment to approval. This is a classic picture for biotech companies in the R&D phase.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772588559252 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Solid Biosciences Inc. (SLDB)
Solid Biosciences is a biotech company developing gene therapy for Duchenne muscular dystrophy. This chart reflects the company's activities at the research stage. Revenue per employee is virtually nonexistent, as all efforts are focused on clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Solid-Biosciences-Inc.-SLDB&v=1772588559281 "Sales chart per company employee Solid Biosciences Inc. (SLDB)")
Sales per employee in the market segment - Dna
Solid Biosciences is a biotech company focused on gene therapy for Duchenne muscular dystrophy. This chart shows the average revenue per employee in this segment. For a clinical-stage company, this is a benchmark for productivity in a sector where success depends on R&D results, not current sales.
Sales per employee for the market as a whole
Solid Biosciences is a clinical-stage biotechnology company specializing in gene therapy for Duchenne muscular dystrophy. They have no commercial products. This figure would be zero, as their team of scientists is entirely focused on R&D and clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Solid Biosciences Inc. (SLDB)
Solid Biosciences is a biotech company focused on gene therapy for Duchenne muscular dystrophy. The bearish sentiment seen in this chart reflects a history of failures and safety concerns. Bears are betting that clinical trials will fail again or that competitors (Sarepta) will be more successful.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Solid-Biosciences-Inc.-SLDB&v=1772588559372 "Short Shares Chart for the Company Solid Biosciences Inc. (SLDB)")
Shares shorted by market segment - Dna
Solid Biosciences is a biotech company focused on gene therapy for Duchenne muscular dystrophy. This chart illustrates the overall sentiment in the sector. It reflects the high investor skepticism toward companies working in this complex field, where the risks of clinical failure and side effects are extremely high.
Shares shorted by the overall market
Solid Biosciences is a clinical-stage biotech company working on gene therapy. Its survival depends on access to funding. When this market pessimism indicator rises, the window for raising capital slams shut. Investors panic and flee unprofitable, speculative ventures like SLDB.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Solid Biosciences Inc. (SLDB)
Solid Biosciences (SLDB) is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy (DMD). This is a complex field with binary risks. This chart measures hype. It shows "overheated" (above 70) on positive clinical trial data or "oversold" (below 30) on news of side effects or delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Solid-Biosciences-Inc.-SLDB&v=1772588559459 "RSI 14 indicator chart for the company's stock Solid Biosciences Inc. (SLDB)")
RSI 14 Market Segment - Dna
Solid Biosciences (SLDB) is a biotech company focused on developing gene therapy for Duchenne muscular dystrophy (DMD). This chart tracks the collective sentiment in the DNA/Genomic Technologies sector. It shows when the entire industry is overheated by hype surrounding breakthroughs or oversold by failures in DMD treatments.
RSI 14 for the overall market
Solid Biosciences (SLDB) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SLDB (Solid Biosciences Inc.)
Solid Biosciences (SLDB) is a biotech company specializing in gene therapy for Duchenne muscular dystrophy (DMD). The company is developing a new generation of microdystrophin to treat this devastating disease. This chart shows the average Wall Street forecast. It reflects analysts' assessments of clinical data and competition in the DMD treatment field.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SLDB-Solid-Biosciences-Inc.&v=1772588559562 "A chart showing analyst consensus forecasts for the expected stock price. SLDB (Solid Biosciences Inc.)")
The difference between the consensus estimate and the actual stock price SLDB (Solid Biosciences Inc.)
Solid Biosciences (SLDB) is a biotech company developing gene therapy for Duchenne muscular dystrophy (DMD). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their complex clinical programs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SLDB-Solid-Biosciences-Inc.&v=1772588559590 "A chart showing the difference between the consensus forecast and the actual stock price. SLDB (Solid Biosciences Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Solid Biosciences is a biotechnology company dedicated to the fight against Duchenne muscular dystrophy (DMD). The company is developing gene therapy for this devastating disease. This chart shows analysts' overall expectations for the DNA technology sector, reflecting whether experts believe gene therapy will be successful in this competitive market.
Analysts' consensus forecast for the overall market share price
Solid Biosciences is a biotechnology company developing gene therapy for Duchenne muscular dystrophy. This chart shows the overall risk appetite. For Solid, which operates in the high-risk field of gene therapy, overall market optimism is critical to attracting the capital needed to fund lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Solid Biosciences Inc.
Solid Biosciences (SLDB) is a biotech company focused on gene therapy for Duchenne muscular dystrophy (DMD). This is their sole focus, and they are a competitor to Sarepta. This chart represents a binary R&D bet. Its valuation reflects the market's faith in their scientific approach (microdystrophin) and their ability to catch up (and possibly surpass) Sarepta.
AKIMA Market Segment Index - Dna
Solid Biosciences (SLDB) is a clinical-stage biotech focused on gene therapy for Duchenne muscular dystrophy (DMD) (a competitor of Sarepta). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (DMD) R&D rate (SLDB) differentiate it from the average pharma company?
The AKIM Index for the overall market
Solid Biosciences is a biotech company developing gene therapy for Duchenne muscular dystrophy. Its focus is improving gene delivery. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story, rebounding from setbacks, compares to overall economic trends and risk appetite.
